http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008081806-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7417827307c66a84b5e7c3a6bb127785 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 |
| filingDate | 2006-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a67678f414d520c32d138b0ac55b992a |
| publicationDate | 2008-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2008081806-A1 |
| titleOfInvention | Treatment for Parkinson's Disease-combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| abstract | A new treatment methodology and pharmacological composition for the treatment and remission of Parkinson's Disease and other neurological diseases are provided. The medication and treatment are based on the use of a combination of a phosphodiesterase inhibitor medication, commonly used to treat male erectile dysfunction, and a high-dose of serotonergic synaptic reuptake inhibitor medication, commonly used to treat depression, anxiety disorders, obsessive compulsive disorder and various panic phobias. n The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers. It has been determined that this dysfunction can be overcome by increasing the levels of the ligands and neurotransmitters cyclic-GMP and serotonin and the consequential increased binding of these ligands and neurotransmitters to efferent neuron receptors in the synapse. Testing indicates that the inventive treatment changes Parkinson's Disease from a debilitating, progressive, frightening, and previously untreatable pre-morbid condition to one that is rapidly reversible. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010298255-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011034471-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8841300-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8440671-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008144061-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008144061-A2 |
| priorityDate | 2006-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.